OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease by Zhang, B.-C. (Bu-Chun) et al.
Drug-eluting stents (DES) have reduced 
the rates of target vessel revascularization 
and comprise the mainstay of treatment 
in percutaneous coronary intervention. 
However, despite the excellent short- and 
mid-term results with the current DES 
generation, ongoing stent failure with 
both bare metal stents (BMS) and DES 
is a frequent finding very late after stent 
implantation [1–3]. Very late stent failure 
clinically manifests as very late restenosis 
or stent thrombosis. Although the patho-
genesis of (very) late stent failure appears 
to be multifactorial [4, 5], one of the ma-
jor mechanisms that have been implicated 
is the de novo development of atheroscle-
rosis within the neointimal region, called 
neoatherosclerosis [6, 7]. Observations of 
neoatherosclerosis have been document-
ed both in ex vivo pathological observa-
tions and in vivo by intravascular imag-
ing.
Among several imaging modalities 
that have been used to identify neoath-
erosclerosis [8–11], optical coherence to-
mography (OCT) can provide the most 
comprehensive assessment of the neo-
intimal tissue. OCT allows for the visual-
ization of the micromorphology of coro-
nary arteries with near-histological reso-
lution, differentiating between individu-
al plaque components and providing im-
portant quantitative plaque information 
as the thickness of the fibrous plaque [12, 
13]. Thus, by OCT it is possible to assess 
distinct morphological characteristics of 
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Fig. 1 9 Morphological 
characteristics of in-stent 
neoatherosclerosis on opti-
cal coherence tomography 
images. a In-stent necrot-
ic core (yellow) within the 
neointima (green).  
b In-stent calcification 
(white) and macrophage in-
filtration (orange). c Neo-
intimal rupture. d In-stent 
necrotic core (yellow) with 
thin overlying fibrous cap. 
Panels on the right are col-
or-coded cartoons of the 
corresponding OCT images, 
explaining the composition 
of the neointimal tissue.
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neoatherosclerosis, such as macrophage 
infiltration, lipid accumulation, in-stent 
calcification, or neointimal rupture. Con-
sequently, in vivo OCT studies have fo-
cused on studying in-stent neoathero-
sclerosis and its association with late stent 
failure. This review summarizes the cur-
rent insights into neoatherosclerosis ob-
tained with OCT and discusses the im-
plications of neoatherosclerosis on long-
term outcome after stent implantation.
Definition and OCT imaging 
evidence of in-stent 
neoatherosclerosis
Neoatherosclerosis refers to an athero-
sclerotic change in neointimal tissue, 
first described in pathologic specimens 
of BMS, and more recently in pathologic 
specimens of DES as well [6, 7]. Although 
observations of neoatherosclerosis had 
been sporadically documented from the 
early application of OCT [14, 15], the tis-
sue properties of the observed neointi-
mal tissue patterns were unknown. Path-
ological studies were the first to provide 
more comprehensive insights regarding 
the histological composition of this enti-
ty. These studies defined neoatherosclero-
sis as the presence of clusters of lipid-lad-
en foamy macrophages with or without 
necrotic core formation and/or calcifica-
tion within the neointimal tissue of stent-
ed segments [6]. The presence of mor-
phological components of native athero-
sclerosis within the neointimal tissue im-
plies that these features can be identified 
by OCT, which has a high accuracy for 
detection of these characteristics in na-
tive atherosclerotic plaques. This hypoth-
esis has been corroborated by a pathologic 
study of ex vivo stented coronary arteries, 
imaged by OCT, which showed that the 
OCT appearance of these characteristics 
is similar to that in native atherosclero-
sis [16]. Components of neoatherosclero-
sis that can be visualized by OCT include 
macrophage infiltration, necrotic core, in-
stent calcifications, and neoatherosclerot-
ic plaque rupture [17]. An in-stent necrot-
ic core visualized by OCT is defined as the 
presence of signal-poor, highly attenuat-
ing regions with poorly delineated bor-
ders within the neointima, while in-stent 
calcifications are defined as well-delineat-
ed, signal-poor regions with sharp bor-
ders [16]. In accordance with native ath-
erosclerosis, macrophages on OCT ap-
pear as a thin signal-bright layer caus-
ing high attenuation, while neointimal 
plaque rupture appears as a discontinu-
ation in the luminal surface with forma-
tion of a cavity burrowing into the neo-
intima [16]. Representative OCT images 
of in-stent neoatherosclerosis are shown 
in . Fig. 1.
At this point it is important to em-
phasize the difference of neoatheroscle-
rosis with the previously reported het-
erogeneous and layered patterns of cov-
erage [18]. These patterns are respective-
ly defined as neointimal tissue with focal-
ly changing optical properties and varying 
backscattering patterns, and as neointi-
mal tissue with concentric layers having 
different optical properties (an adluminal 
high scattering layer and an abluminal 
low scattering layer). Such patterns are of-
ten encountered in the context of in-stent 
restenosis, and although the pathological 
substrate is not well characterized, histo-
logical findings from atherectomy speci-
mens, autopsy, and animal experiments 
include organized thrombus, fibrin, and 
myxomatous extracellular matrix with 
sporadic evidence of inflammation [16, 
19–21]. The association of these patterns 
with neoatherosclerosis is yet unknown, 
however there is evidence that these pat-
terns similar to the homogeneous pattern 
may subsequently be replaced by neoath-
erosclerotic tissue [22, 23]. Representative 
OCT images of different neointimal cov-
erage patterns are shown in . Fig. 2.
Although OCT can discern the distinct 
morphological characteristics of neoath-
erosclerosis, caution should be applied 
to image interpretation. This is because 
macrophage infiltration can sometimes 
appear as in-stent necrotic core, and vice 
versa [24]. Also, the distinction of a lay-
ered pattern of coverage with in-stent ne-
crotic core can also be challenging some-
Fig. 2 8 Patterns of neointimal coverage as visualized on optical coherence tomography images.  
a Homogeneous pattern (green); b heterogeneous pattern (light gray); c layered pattern (dark gray). 
Panels on the bottom right are color-coded cartoons of the corresponding OCT images, explaining the 
composition of the neointimal tissue.
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times, although the low attenuation ob-
served in the case of the layered pattern 
can be used to discriminate between these 
two entities [16]. Finally, with OCT it is 
not possible to distinguish between true 
adluminal atherosclerosis from the pro-
gression of an abluminal underlying ne-
crotic core into the neointima. Neverthe-
less, the latter mechanism appears to be 
less prevalent [25], while it is unclear what 
the clinical significance of such a discrim-
ination would be.
In vivo prevalence of 
neoatherosclerosis in 
BMS and DES with OCT
Several studies have tried to investigate 
the prevalence of neoatherosclerosis late 
after BMS or DES implantation using 
OCT (. Table 1). The reported prevalence 
varies highly between the studies. As these 
studies differ significantly in stent type, in 
the interval between stent implantation 
and follow-up, and in the clinical presen-
tation, this difference in prevalence ap-
pears to reflect differences in the compo-
sition of the studied population. The first 
reports of in-stent neoatherosclerosis re-
port a prevalence of 67 % in patients with 
BMS implantation beyond 5 years [15]. 
Subsequent studies have shown lower 
prevalence ranging between 30 and 50 % 
in long-term follow-up of asymptomat-
ic patients with BMS [26–28]; however, 
this incidence could be as high as 100 % 
in BMS restenosis more than 10 years 
since implantation [29]. With regard to 
neoatherosclerosis within DES, a preva-
lence of more than 50 % has been report-
ed in a very late follow-up [27, 28], which 
can be even higher in stents with failure 
[14]. These rates tend to generally be in 
accordance with rates reported by path-
ological studies, which show a prevalence 
of 13–65 % depending on stent type and 
stent age [25].
Major factors associated with 
in-stent neoatherosclerosis
Stent type and age
Pathological studies were the first to in-
dicate a potential association of stent type 
and stent age with the prevalence of neo-
atherosclerosis [6]. DES appear to have a 
higher prevalence of neoatherosclerosis 
compared with BMS. Moreover, irrespec-
tive of stent type, the interval from im-
plantation appears to be strongly associat-
ed with neoatherosclerosis development, 
an interval which is much lower than the 
interval required for development of na-
tive atherosclerotic plaques [25]. Naka-
zawa et al. [6] first demonstrated an in-
creased prevalence of neoatherosclerosis 
in autopsy specimens of first-generation 
DES compared with BMS despite a short-
er interval from implantation. Important-
ly, in both groups, the prevalence of neo-
atherosclerosis increased with the inter-
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Abstract
Although the advent of drug-eluting stents 
has reduced the rates of target vessel revas-
cularization, there are observations of ongo-
ing stent failure occurring very late after stent 
implantation and presenting as very late re-
stenosis or as very late stent thrombosis. 
The de novo development of atherosclero-
sis within the neointimal region, called neo-
atherosclerosis, has been identified as one of 
the pathomechanisms of these observed late 
stent failures. The mechanisms of neoath-
erosclerosis development and its association 
with stent failure are currently the subject of 
intensive research. Optical coherence tomog-
raphy (OCT) is an invasive imaging modality 
that allows us to visualize the micromorphol-
ogy of coronary arteries with near-histologi-
cal resolution, thus providing detailed assess-
ment of the morphological characteristics of 
the neointima after stent implantation, in-
cluding neoatherosclerosis. Several OCT stud-
ies have tried to provide in vivo insights in the 
mechanisms of neoatherosclerosis develop-
ment and its association with late stent fail-
ure. This review summarizes the current in-
sights into neoatherosclerosis obtained with 
OCT and discusses the association of neoath-
erosclerosis with late stent failure.
Keywords
Atherosclerosis · Optical coherence 
tomography · Percutaneous coronary 
intervention · Drug-eluting stents · Bare 
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OCT-Nachweis einer Neoatherosklerose als Teil des 
fortlaufenden Prozesses der koronaren Herzkrankheit
Zusammenfassung
Zwar ist es durch das Aufkommen medika-
mentenbeschichteter Stents zu einer Sen-
kung der Rate von Zielgefäßrevaskularisie-
rungen gekommen, aber es wurden Fälle 
fortlaufenden Stentversagens beobachtet, 
die erst sehr spät nach Stentimplantation auf-
treten und sich mit großer zeitlicher Verzöge-
rung als Restenosierung oder als sehr späte 
Stentthrombose manifestieren. Das De-novo-
Auftreten einer Atherosklerose innerhalb der 
neointimalen Region, als Neoatherosklero-
se bezeichnet, hat sich als einer der Pathome-
chanismen dieser späten Fälle von Stentver-
sagen herausgestellt. Die Mechanismen der 
Neoatheroskleroseentstehung und ihr Zu-
sammenhang mit einem Stentversagen wer-
den derzeit noch intensiv untersucht. Die op-
tische Kohärenztomographie (OCT) ist ein in-
vasives bildgebendes Verfahren, mit dem sich 
die Mikromorphologie der Koronararterien in  
nahezu histologischer Auflösung darstellen 
lässt und das somit eine detaillierte Beurtei-
lung der morphologischen Merkmale der Ne-
ointima nach Stentimplantation, einschließ-
lich Neoatherosklerose, ermöglicht. Im Rah-
men verschiedener OCT-Studien wurde ver-
sucht, in vivo einen Einblick in die Mechanis-
men der Neoatheroskleroseentstehung und 
ihren Zusammenhang mit spätem Stentver-
sagen zu erhalten. In der vorliegenden Über-
sichtsarbeit wurde der Schwerpunkt auf die 
zusammenfassende Darstellung aktueller Er-
kenntnisse aus der OCT in Bezug auf die Ne-
oatherosklerose gelegt und der Zusammen-
hang der Neoatherosklerose mit spätem 
Stentversagen erörtert.
Schlüsselwörter
Atherosklerose · Optische 
Kohärenztomographie · 
Perkutane Koronarintervention · 
Medikamentenbeschichtete Stents · Reine 
Metallstents
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val since implantation [6]. In vivo OCT 
studies have been in line with patholog-
ical studies showing an increased prev-
alence of neoatherosclerosis in DES at a 
follow-up of up to 4 years, although at a 
very long-term follow-up the prevalence 
is similarly high for both stent types [30]. 
Furthermore, serial imaging observations 
in first- and second-generation DES dem-
onstrate that neointimas with a homoge-
neous or heterogeneous pattern of cov-
erage might develop neoatherosclero-
sis over time with the prevalence of neo-
atherosclerosis increasing from 15 % at 
9 months to 28 % at 24 months since im-
plantation [22]. This was further corrob-
orated by another serial imaging study in 
first-generation DES where the incidence 
of neoatherosclerosis increased from 3 % 
at mid-phase observations (3–12 months 
after stent implantation) to 23 % at late-
phase observations [23].
Although DES in general appear to 
have a higher prevalence of neoathero-
sclerosis than BMS, it is not clear wheth-
er the prevalence of neoatherosclerosis 
differs between first- and second-gener-
ation DES. Second-generation DES have 
improved biocompatibility due to thin-
ner struts and more biocompatible or 
bioabsorbable polymers, which trans-
lates to lower vascular toxicity and hy-
persensitivity reactions [31, 32]. Howev-
er, a human autopsy study did not dem-
onstrate any significant difference in the 
prevalence of neoatherosclerosis between 
a second-generation DES, cobalt-chro-
mium everolimus-eluting stent (CoCr-
EES), and first-generation paclitaxel-elut-
ing (PES) or sirolimus-eluting stent (SES): 
CoCr-EES = 29 %; SES = 35 %; PES = 19 % 
[32]. Conversely, an in vivo OCT study in 
212 DES-treated patients with > 50 % ste-
nosis (101 patients had a first-generation 
and 111 patients had a second-generation 
DES) demonstrated a significantly lower 
prevalence of neoatherosclerosis in the 
second-generation DES group (10.8 vs. 
45.5 %, p < 0.001); however, this difference 
was not significant after adjusting for time 
since implantation [33]. Similar findings 
were observed with OCT in a comparison 
of the coronary arterial response in biode-
gradable polymer biolimus-eluting stents 
(BES) versus durable polymer SES and 
BMS at the 5-year follow-up. The num-
ber of cross sections with neoatheroscle-
rosis within BES was similar to BMS (BES 
= 2.26 % vs. BMS = 2.23 %, p = 0.98) and 
tended to be lower than SES (BES = 2.26 % 
vs. SES = 9.90 %, p = 0.07) [34].
The reasons why the temporal course 
of atherosclerosis within stents is accel-
erated are not well understood; however, 
dysfunction of endothelial cells, which are 
barriers that prevent lipid infiltration and 
Table 1 Reported prevalence of neoatherosclerosis assessed by OCT in late stent follow-up 
studies
Study Indication (n) Stent type (n) Follow-up duration Prevalence (%)
Takano et al. [15] Follow-up (21) BMS (21) ≥ 5 years 67
Kitabata et al. 
[27]
Follow-up (36) 1st and 2nd DES 
(19)
BMS (17)
60 months
126 months
59
42
Kim et al. [22] Follow-up (76) 1st and 2nd DES 
(76)
9 months
2 years
15
28
Kozuki et al. [23] Follow-up (62) 1st DES (62) 3–12 months
36–80 months
3
23
Yonetsu et al. 
[30]
Follow-up (138) 1st and 2nd DES 
(82)
BMS (56)
 9 months
9–48 months
≥ 48 months
 9 months
9–48 months
≥ 48 months
37
63
75
8
28
77
Kuramitsu et al. 
[34]
Follow-up (33) 2nd DES (12)
1st DES (11)
BMS (10)
5 years 2 (frames)
10 (frames)
2 (frames)
Kitabata et al. 
[41]
Follow-up (46) BMS (46) ≥ 4 years 47
Tian et al. [36] Follow-up (109) DES (109) 1 year 13.8
Hou et al. [26] Follow-up (60) BMS (60) 7 ± 1 years 33
Kang et al. [9] Restenosis (50) 1st and 2nd DES 
(50)
32 (9–52) months 90
Kang et al. [29] Restenosis (22) BMS (22) 132 ± 31 months 100
Ino et al. [38] Restenosis (48) 1st DES (48) 8 ± 1 months
34 ± 14 months
27
83
Ali et al. [8] Restenosis (65) 1st and 2nd DES 
(51)
BMS (14)
33 (16–60) months
36 (15–113) months
68
36
Habara et al. [45] Restenosis (86) 1st DES (86)  1 year
1–3 years
 3 years
2
14
35
Lee et al. [33] Restenosis 
(212)
1st DES (111)
2nd DES (101)
55 months
12 months
46
11
Ko et al. [54] Stent thrombo-
sis (18)
1st and 2nd DES 
(18)
42 ± 21 months 22
Amabile et al. 
[50]
Stent thrombo-
sis (20)
1st DES (4) and 
BMS(16)
8 (1–18) years 50
Amioka et al. 
[51]
Stent thrombo-
sis (23)
1st DES (13)
BMS (10)
1,750 ± 770 days
3,224 ± 1,380 days
46
50
Kang et al. [52] Stent thrombo-
sis (33)
1st DES (27)
BMS (6)
Median: 62 months
Median: 110 months
56
100
Alfonso et al. 
[67]
Stent thrombo-
sis (15)
BMS(8) and DES 
(7)
Median: 347 days 27
Karanasos et al. 
[49]
Follow-up (22)
Restenosis (13)
Thrombosis 
(39)
BMS (13)/1st and 
2nd DES (61)
≥ 18 months
Median: 63 months
32
85
67
BMS bare metal stents, 1st DES first-generation drug-eluting stents, 2nd DES second-generation drug-eluting 
stents, OCT optical coherence tomography.
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migration of inflammatory cells, has been 
considered to be the main mechanism. 
This mechanism can also explain the in-
creased prevalence of neoatherosclerosis 
observed in DES, where local drug deliv-
ery inhibits neointimal hyperplasia, caus-
ing delayed coverage and dysfunction of 
endothelial cells [35].
Clinical factors
In addition to the stent type and age, sev-
eral patient characteristics have been as-
sociated with neoatherosclerosis. Two 
registries of late stent follow-up have both 
identified chronic kidney disease as a fac-
tor independently associated with neo-
atherosclerosis [28, 33]. Other identified 
factors included low-density lipopro-
tein cholesterol > 70 mg/dl [33], current 
smoking, and lack of treatment with an-
giotensin-converting enzyme inhibitors 
or angiotensin II receptor blockers [28]. 
In another study, the presence of diabetes 
mellitus was associated with a higher inci-
dence of neoatherosclerosis at a late DES 
follow-up (18.3 vs. 5.5 %, p = 0.03) [36]. 
Further subgroup analysis showed that el-
evated glycated hemoglobin (HbA1c) lev-
els (> 7 %) in patients with diabetes mel-
litus were associated with a higher inci-
dence of neoatherosclerosis (28 vs. 7 %, 
p = 0.048).
Plaque and stent characteristics
Plaque characteristics have also been im-
plicated in the neoatherosclerotic process. 
Microvessels play a key role in advanced 
atherosclerosis, which is closely associat-
ed with plaque hemorrhage and plaque 
rupture [37], while previous investiga-
tions have demonstrated a higher inci-
dence of microvessels in late in-stent re-
stenotic tissue, suggesting that neovessels 
might be a trigger for in-stent neoathero-
sclerosis [38, 39]. Moreover, a spatial cor-
respondence of neoatherosclerosis and 
microvessels was identified at a follow-up 
OCT examination of BMS and DES [40], 
supporting the hypothesis of microves-
sel involvement in neoatherosclerosis de-
velopment. In the same study, neoath-
erosclerosis was more frequently identi-
fied in the proximal and distal stent sec-
tions, also associated with the morphol-
ogy of the adjacent vessel segment. Spe-
cifically, the presence of lipid plaque in 
the adjacent stent edges was associat-
ed with the presence of neoatherosclero-
sis at the stent edges, implying that pro-
gression of native disease might also con-
tribute to neoatherosclerosis. Apart from 
plaque characteristics, stent characteris-
tics such as strut thickness seem to play 
a role even among the same stent type. In 
a study assessing the prevalence of neo-
atherosclerosis in BMS at a long-term 
follow-up (≥ 4 years after implantation), 
thick-strut stents (≥ 100 µm) had a high-
er prevalence of neoatherosclerosis com-
pared with thin-strut stents (70 vs. 32 %, 
p = 0.02) [41].
Neoatherosclerosis and 
in-stent restenosis
Although early in-stent restenosis main-
ly results from aggressive neointimal pro-
liferation [42], recent data also suggest 
that neoatherosclerosis may play an im-
portant pathophysiological role, especial-
ly in late restenosis. Pathological studies 
have demonstrated that neoatherosclero-
sis represents a common substrate in pa-
tients with late stent failure [43], while in 
vivo OCT studies have further elucidated 
the role of neoatherosclerosis in the devel-
opment of late stent failure (. Fig. 3). The 
presence of neoatherosclerosis has been 
Fig. 3 9 Late restenosis 
due to neoatherosclero-
sis. a Angiogram of patient 
presenting with stable an-
gina 15 years after sirolim-
us-eluting stent implanta-
tion reveals a possible re-
stenotic lesion in the site 
of the previously implant-
ed stent. Optical coherence 
tomography study reveals 
a homogeneous pattern of 
coverage (green) proximal 
to the stent (b), but with 
neoatherosclerosis devel-
opment (yellow) at the dis-
tal segment (c and d) caus-
ing lumen compromise. 
Panels on the right are col-
or-coded cartoons of the 
corresponding OCT images, 
explaining the composition 
of the neointimal tissue.
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associated with a higher degree of neointi-
mal hyperplasia, independent from stent 
type and time since implantation [44]. Al-
though during the early phases after DES 
implantation, homogeneous or heteroge-
neous patterns of coverage are the pre-
dominant pathology in in-stent resteno-
sis, in later follow-up intervals resteno-
sis is often associated with the presence 
of neoatherosclerosis [38, 45]. A study fo-
cusing on 50 patients with DES resteno-
sis at a median follow-up of 32 months 
since implantation showed a prevalence 
of neoatherosclerosis of 52 % [9]. Also, in 
lesions with very late BMS restenosis be-
yond 10 years since implantation, neo-
atherosclerosis was detected in 100 % of 
the stents with a high frequency of neo-
intimal rupture and neointimal thrombi 
[29]. However, a comparison of restenot-
ic lesions of DES and BMS showed that 
neoatherosclerosis occurs earlier in DES 
compared with BMS and develops more 
diffusely along stented vessels with thin-
ner cap and greater total lipid core [8]. 
Whether the contribution of neoathero-
sclerosis in restenosis of second-genera-
tion DES is similar to that of first-genera-
tion DES is not well established; however, 
observations of restenosis due to neoath-
erosclerosis have also been reported for 
second-generation DES [33].
Neoatherosclerosis and 
stent thrombosis
Neoatherosclerosis also appears to con-
tribute to the development of (very) late 
stent thrombosis (. Fig. 4). Initial path-
ological studies demonstrated a role for 
the underlying plaque in BMS thrombo-
sis, while subsequent studies in DES in-
criminated an impaired healing response 
with high rates of uncovered struts and 
vascular toxicity-associated malapposi-
tion as the main pathogenetic factor [46, 
47]. Nevertheless, more recent pathologi-
cal and intracoronary imaging data sup-
port the hypothesis that neoatherosclero-
sis is an active causal mechanism in a high 
percentage of cases with late stent throm-
bosis [32, 48, 49]. Autopsy studies have 
shown that thrombosis might develop on 
the grounds of neointimal plaque rupture 
[32], while thrombus aspirate samples 
from patients with very late BMS throm-
bosis demonstrate the presence of ath-
erosclerotic plaque components such as 
foamy macrophages and cholesterol crys-
tals within the aspirates [48]. Simultane-
ously, a number of studies have examined 
the OCT findings in patients with late and 
very late stent thrombosis, in an attempt 
to identify the pathomechanisms [50–54]. 
Despite minor discrepancies in the exact 
prevalence of neoatherosclerosis and the 
relative contribution of neointimal plaque 
rupture in each study, these studies col-
lectively demonstrate a very high preva-
lence of plaque rupture as a pathomech-
anism for very late BMS thrombosis [55], 
and an almost equal contribution for neo - 
Fig. 4 9 Very late throm-
bosis due to neoatheroscle-
rosis. a Angiogram of pa-
tient presenting with ST-el-
evation myocardial infarc-
tion 7 years after everolim-
us-eluting stent implanta-
tion in the right coronary 
artery showing total occlu-
sion. After thrombus as-
piration an in-stent lesion 
is obvious (b), while opti-
cal coherence tomography 
study shows neoathero-
sclerosis development (yel-
low) with neointimal rup-
ture leading to cavity for-
mation (Cav) and thrombus 
(red) (c–f). Homogeneous 
neointima is indicated in 
green. Panels on the bot-
tom are color-coded car-
toons of the corresponding 
OCT images, explaining the 
composition of the neointi-
mal tissue.
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intimal plaque rupture and impaired heal - 
ing in (very) late DES thrombosis [50, 52, 
53]. Compared to an impaired healing re - 
sponse, neointimal rupture is a mecha-
nism occurring mainly at longer intervals 
since stent implantation [50, 56], in neo-
intimal regions with high necrotic core 
content and thin fibrous cap, similarly to 
what is observed in native atherosclero-
sis, but also with a very high incidence of 
macrophage infiltration [49].
Evidence also suggests that the clinical 
presentation of late stent failure is not ex-
clusively affected by the presence of neo-
atherosclerosis but also by the morpho-
logical characteristics. In patients with 
in-stent restenosis, a higher incidence of 
OCT-defined thin-cap fibroatheroma, 
intimal rupture, and thrombi was iden-
tified in patients presenting with unsta-
ble angina compared with patients with 
stable symptoms [9]. Our group inves-
tigated the differences in the prevalence 
of neoatherosclerosis with regard to the 
clinical presentation [49]. Both stent re-
stenosis and stent thrombosis had a high-
er prevalence of neoatherosclerosis com-
pared with the asymptomatic group (stent 
thrombosis: 67 % vs. restenosis: 85 % vs. 
asymptomatic: 32 %; p < 0.001). Howev-
er, the prevalence of neointimal rupture 
was higher in the stent thrombosis group 
(stent thrombosis: 41 % vs. restenosis: 
15 % vs. asymptomatic: 5 %; p < 0.001) 
(. Fig. 5a). This finding underscores the 
contribution of neoatherosclerosis devel-
opment in the pathogenesis of late stent 
failure, while it indicates that neointimal 
rupture is mainly associated with acute 
presentation, although not infrequently 
encountered in stable or asymptomatic 
in-stent lesions.
Overall, intravascular imaging has 
changed the understanding of the patho-
genesis of late restenosis and thrombosis 
by disclosing that neoatherosclerosis is a 
common pathomechanism in both enti-
ties (. Fig. 5b). Stent restenosis had tra-
ditionally been considered a rather be-
nign entity associated with stable symp-
toms, while stent thrombosis was seen as 
a life-threatening entity associated with 
acute presentation, with these two enti-
ties considered to be associated with dif-
ferent pathogenetic substrates. Howev-
er, the presence—to a different extent—
of common imaging findings such as in-
stent necrotic core, neointimal rupture, 
and thrombus in both entities implies 
that these two presentations can occur as 
different manifestations of the same unfa-
vorable healing process.
Neoatherosclerosis and 
bioresorbable scaffolds
Bioresorbable vascular scaffolds (BVS) 
are a new technology for percutaneous 
revascularization that are resorbed after 
an interval of 2–4 years since implanta-
tion. Conceptually, after this interval, the 
permanent vessel caging with the associ-
ated endothelial dysfunction disappears 
and this can lead to a reduction of stent-
induced complications such as hypersen-
sitivity reactions or neoatherosclerosis. 
First-in-man studies of BRS have demon-
strated a favorable healing response at a 
very long-term follow-up with complete 
strut reabsorption, late luminal enlarge-
ment, and a potentially favorable plaque 
modification, while no cases of necrot-
ic core accumulation of adluminal origin 
were observed [57]. As after bioresorp - 
tion, the area corresponding to struts and 
neointima is consolidated with the under-
lying plaque, it resembles a native athero-
sclerotic plaque that is now well separated 
by the lumen by a signal-rich layer, a pro-
cess modulated by hemodynamic factors 
[58] (. Fig. 6). Nevertheless, as these first-
in-man studies have focused on simple le-
sions, data on more complex lesions in-
cluding thrombotic lesions are scarce [59]. 
Studies on more complex populations are 
ongoing, without, however, any worrying 
signs regarding neoatherosclerosis devel-
opment in human studies of BVS thus far. 
Moreover, studies reporting on (very) late 
BVS thrombosis have not shown any evi-
dence of scaffold thrombosis due to neo-
intimal plaque rupture [60]. Therefore, the 
further development and implementation 
in the clinical practice of bioresorbable 
technologies might allow these complica-
tions to be overcome, although more long-
term data are needed to confirm a poten-
tial benefit of this technology.
Fig. 5 8 a Prevalence of neoatherosclerosis and neointimal rupture according to clinical presentation [49]. b Change in the 
understanding of stent failure by intravascular imaging insights. Although stent restenosis had traditionally been consid-
ered a benign entity associated with stable symptoms and stent thrombosis had been considered a life-threatening entity as-
sociated with acute presentation, intravascular imaging has disclosed the participation of neoatherosclerosis in both enti-
ties, with several imaging findings such as in-stent necrotic core, neointimal rupture, and thrombus being common between 
them
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Newer OCT techniques 
for assessment of 
neoatherosclerosis
As previously mentioned, OCT is associ-
ated with some limitations in assessment 
of neoatherosclerosis. Nevertheless, new 
developments in OCT could improve in-
stent tissue characterization and provide 
an enhanced and more objective neointi-
mal tissue characterization. One of these 
developments is quantitative attenuation 
imaging. Tissue properties such as atten-
uation have been shown in ex vivo stud-
ies to be associated with the presence of 
macrophages and/or necrotic core [61, 
62], while in vivo studies have demon-
strated the potential of this technique for 
the detection of lipid plaques and fibro-
atheromas [63]. Therefore, this technique 
could be used for the assessment of neo-
atherosclerosis, since the optical proper-
ties of tissue components such as macro-
phages and a necrotic core are similar be-
tween native atherosclerosis and neoath-
erosclerosis. OCT assessment of neoath-
erosclerosis can also be improved through 
software for automated fibrous cap thick-
ness measurement that can reduce human 
variability in the assessment of in-stent fi-
broatheromas [64]. Furthermore, the ap-
plication of technologies such as polariza-
tion-sensitive OCT in humans can pro-
vide further structural information such 
as collagen and smooth muscle content of 
neointimal tissue [65], while high-speed 
OCT catheters will be able to acquire im-
ages from an entire coronary artery in less 
than 1 s [66].
Conclusion and perspectives
Recent evidence has highlighted the sig-
nificance of in-stent neoatherosclerosis 
as a disease entity that comprises an im-
portant substrate for late adverse cardi-
ac events after stent implantation and 
is one of the major pitfalls of the current 
generation of metallic stents. Patholog-
ical studies have demonstrated that in-
filtration of lipid-laden foamy macro-
phages with or without necrotic core 
and/or calcification formation consti-
tutes the pathological substrate. A num-
ber of in vivo studies have used OCT—
an imaging modality that can accurate-
ly identify morphological characteris-
tics such as in-stent necrotic core, in-
stent calcification, macrophage infiltra-
tion, and neointimal plaque rupture—
in order to assess the in vivo characteris-
tics and implications of this disease en-
tity. These have demonstrated that neo-
atherosclerosis appears earlier and more 
frequently in drug-eluting stents com-
pared with bare metal stents, is associat-
ed with several clinical and morpholog-
ical factors, while its prevalence increas-
es over time. Importantly, an association 
of neoatherosclerosis with late stent fail-
ure has been demonstrated, manifesting 
either as late restenosis, or in cases with 
neointimal plaque rupture as late stent 
thrombosis. Bioresorbable technologies 
hold promise for the reduction of this en-
tity; however, their long-term healing re-
sponse needs to be better document-
ed. Further studies are needed so as to 
demonstrate what the prognostic im-
plications of neoatherosclerosis detec-
tion are, and whether the natural histo-
ry of this disease entity can be modified. 
Meanwhile, new devices for percutane-
ous revascularization need to be devel-
oped that can alleviate this entity, in or-
der to be able to reduce the incidence of 
very late events after percutaneous coro-
nary intervention.
Corresponding address
E. Regar MD, PhD
Department of Cardiology, Thorax Center
Erasmus Medical Center, Room Ba-585 
‘s-Gravendijkwal 230 
3015 Rotterdam
e.regar@erasmusmc.nl
Compliance with 
ethical guidelines
Conflict of interest. B.C. Zhang, A. Karanasos, and E. 
Regar state that there are no conflicts of interest. The 
accompanying manuscript does not include studies 
on humans or animals.
Open Access  This article is distributed under the 
terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, dis-
tribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) 
and the source, provide a link to the Creative Com-
mons license, and indicate if changes were made.
Fig. 6 8 Paradigm of healing response in metal stents and bioresorbable scaffolds. After metal stent 
implantation, struts are preserved and the neointimal area is clearly delineated between the stent and 
lumen contour even at long-term follow-up, with possible development of neoatherosclerosis within 
the neointima. Conversely, in long-term follow-up of bioresorbable scaffolds, neointimal boundaries 
are unclear after bioresorption (dotted line), and the intima resembles a native plaque, defined as neo-
plaque. The signal-rich layer is the layer that separates the underlying plaque components from the lu-
men. BVS bioresorbable vascular scaffold. (Adapted from Karanasos et al. [57])
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